Skip to main content
fr
en
Main navigation
Company
Company profile
Management
Leadership Team
Supervisory Board
Strategic Advisory Board
Our history
Science
Scientific approach
Innate Immunity & NK cells
Antibody formats
ANKET®: Our NK cell engager Platform
Publications
Products
Pipeline overview
Clinical trials
------------------
Lacutamab
Monalizumab
IPH5201
IPH5301
IPH6101
IPH62
IPH6401
IPH6501
Partnering
Investors
Overview
News
Events
Stock Info
Financial and Regulatory Information
General Shareholders Meeting
Governance
Resources
Media
Media hub
All press releases
Media center
Careers
Menu
Home
Media center
CellPress : Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity | Eric Vivier
Thu, 05/30/2019 - 10:30
Category
Science
Company
Company profile
Management
Leadership Team
Supervisory Board
Strategic Advisory Board
Our history
Science
Scientific approach
Innate Immunity & NK cells
Antibody formats
ANKET®: Our NK cell engager Platform
Publications
Products
Pipeline overview
Clinical trials
------------------
Lacutamab
Monalizumab
IPH5201
IPH5301
IPH6101
IPH62
IPH6401
IPH6501
Partnering
Investors
Overview
News
Events
Stock Info
Financial and Regulatory Information
General Shareholders Meeting
Governance
Resources
Investisseurs
Accueil investisseurs
News
Evènements
L'action
Information réglementée et publications
Assemblées Générales des actionnaires
Gouvernement d’entreprise
Innate en actions - le Club
Inscription au Club
Règles de fonctionnement
Kit Investisseur
Media
Media hub
All press releases
Media center
Careers
